CRDF
Price
$2.87
Change
-$0.14 (-4.65%)
Updated
Apr 3, 04:59 PM (EDT)
Capitalization
190.92M
27 days until earnings call
ORMP
Price
$2.16
Change
-$0.04 (-1.82%)
Updated
Apr 3 closing price
Capitalization
87.83M
54 days until earnings call
Ad is loading...

CRDF vs ORMP

Header iconCRDF vs ORMP Comparison
Open Charts CRDF vs ORMPBanner chart's image
Cardiff Oncology
Price$2.87
Change-$0.14 (-4.65%)
Volume$35.17K
Capitalization190.92M
Oramed Pharmaceuticals
Price$2.16
Change-$0.04 (-1.82%)
Volume$154.79K
Capitalization87.83M
CRDF vs ORMP Comparison Chart
Loading...
CRDF
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
ORMP
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
CRDF vs. ORMP commentary
Apr 04, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is CRDF is a Buy and ORMP is a Hold.

Ad is loading...
COMPARISON
Comparison
Apr 04, 2025
Stock price -- (CRDF: $2.87 vs. ORMP: $2.16)
Brand notoriety: CRDF and ORMP are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: CRDF: 100% vs. ORMP: 53%
Market capitalization -- CRDF: $190.92M vs. ORMP: $87.83M
CRDF [@Biotechnology] is valued at $190.92M. ORMP’s [@Biotechnology] market capitalization is $87.83M. The market cap for tickers in the [@Biotechnology] industry ranges from $299.64B to $0. The average market capitalization across the [@Biotechnology] industry is $2.21B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

CRDF’s FA Score shows that 0 FA rating(s) are green whileORMP’s FA Score has 0 green FA rating(s).

  • CRDF’s FA Score: 0 green, 5 red.
  • ORMP’s FA Score: 0 green, 5 red.
According to our system of comparison, ORMP is a better buy in the long-term than CRDF.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

CRDF’s TA Score shows that 4 TA indicator(s) are bullish while ORMP’s TA Score has 3 bullish TA indicator(s).

  • CRDF’s TA Score: 4 bullish, 5 bearish.
  • ORMP’s TA Score: 3 bullish, 7 bearish.
According to our system of comparison, CRDF is a better buy in the short-term than ORMP.

Price Growth

CRDF (@Biotechnology) experienced а -16.57% price change this week, while ORMP (@Biotechnology) price change was -6.09% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -8.91%. For the same industry, the average monthly price growth was -11.19%, and the average quarterly price growth was -14.86%.

Reported Earning Dates

CRDF is expected to report earnings on May 01, 2025.

ORMP is expected to report earnings on May 28, 2025.

Industries' Descriptions

@Biotechnology (-8.91% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
CRDF($191M) has a higher market cap than ORMP($87.8M). ORMP YTD gains are higher at: -10.744 vs. CRDF (-30.645). ORMP has higher annual earnings (EBITDA): 9.44M vs. CRDF (-48.25M). ORMP has more cash in the bank: 142M vs. CRDF (91.7M). ORMP has less debt than CRDF: ORMP (429K) vs CRDF (1.52M). CRDF has higher revenues than ORMP: CRDF (683K) vs ORMP (0).
CRDFORMPCRDF / ORMP
Capitalization191M87.8M218%
EBITDA-48.25M9.44M-511%
Gain YTD-30.645-10.744285%
P/E RatioN/A20.91-
Revenue683K0-
Total Cash91.7M142M65%
Total Debt1.52M429K355%
FUNDAMENTALS RATINGS
CRDF vs ORMP: Fundamental Ratings
CRDF
ORMP
OUTLOOK RATING
1..100
5283
VALUATION
overvalued / fair valued / undervalued
1..100
64
Fair valued
68
Overvalued
PROFIT vs RISK RATING
1..100
89100
SMR RATING
1..100
9885
PRICE GROWTH RATING
1..100
6561
P/E GROWTH RATING
1..100
10045
SEASONALITY SCORE
1..100
n/a36

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

CRDF's Valuation (64) in the null industry is in the same range as ORMP (68) in the Pharmaceuticals Other industry. This means that CRDF’s stock grew similarly to ORMP’s over the last 12 months.

CRDF's Profit vs Risk Rating (89) in the null industry is in the same range as ORMP (100) in the Pharmaceuticals Other industry. This means that CRDF’s stock grew similarly to ORMP’s over the last 12 months.

ORMP's SMR Rating (85) in the Pharmaceuticals Other industry is in the same range as CRDF (98) in the null industry. This means that ORMP’s stock grew similarly to CRDF’s over the last 12 months.

ORMP's Price Growth Rating (61) in the Pharmaceuticals Other industry is in the same range as CRDF (65) in the null industry. This means that ORMP’s stock grew similarly to CRDF’s over the last 12 months.

ORMP's P/E Growth Rating (45) in the Pharmaceuticals Other industry is somewhat better than the same rating for CRDF (100) in the null industry. This means that ORMP’s stock grew somewhat faster than CRDF’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
CRDFORMP
RSI
ODDS (%)
Bullish Trend 2 days ago
60%
Bearish Trend 2 days ago
81%
Stochastic
ODDS (%)
Bullish Trend 2 days ago
82%
Bullish Trend 2 days ago
81%
Momentum
ODDS (%)
Bearish Trend 2 days ago
89%
Bearish Trend 2 days ago
88%
MACD
ODDS (%)
N/A
Bearish Trend 2 days ago
87%
TrendWeek
ODDS (%)
Bearish Trend 2 days ago
86%
Bearish Trend 2 days ago
81%
TrendMonth
ODDS (%)
Bearish Trend 2 days ago
88%
Bullish Trend 2 days ago
84%
Advances
ODDS (%)
Bullish Trend 10 days ago
88%
Bullish Trend 28 days ago
82%
Declines
ODDS (%)
Bearish Trend 2 days ago
86%
Bearish Trend 3 days ago
83%
BollingerBands
ODDS (%)
Bullish Trend 2 days ago
84%
Bullish Trend 2 days ago
80%
Aroon
ODDS (%)
Bearish Trend 2 days ago
90%
Bearish Trend 2 days ago
83%
View a ticker or compare two or three
Ad is loading...
CRDF
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
ORMP
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
JDVZX15.620.06
+0.39%
JPMorgan Diversified R6
TISLX10.74N/A
N/A
Transamerica Intl Sust Eq R6
NOINX14.96N/A
N/A
Northern International Equity Index
SEUIX25.94N/A
N/A
SEI Large Cap Value I (SIMT)
GMVAX15.30N/A
N/A
Goldman Sachs Small/Mid Cap Value A

CRDF and

Correlation & Price change

A.I.dvisor indicates that over the last year, CRDF has been loosely correlated with MDGL. These tickers have moved in lockstep 46% of the time. This A.I.-generated data suggests there is some statistical probability that if CRDF jumps, then MDGL could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To CRDF
1D Price
Change %
CRDF100%
-1.63%
MDGL - CRDF
46%
Loosely correlated
+3.28%
CMRX - CRDF
44%
Loosely correlated
+0.24%
ORMP - CRDF
39%
Loosely correlated
+3.29%
MRVI - CRDF
38%
Loosely correlated
+2.31%
QURE - CRDF
35%
Loosely correlated
+7.16%
More